Clinical factors associated with hyperkalemia in patients with congestive heart failure

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 3, 2005, Pages 233-239

  Ramadan, Fadi H ^a   Masoodi, N ^b   El Solh, A A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Congestive heart failure; Hyperkalemia; Risk factors

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; SPIRONOLACTONE; CARDIOVASCULAR AGENT; CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; RISK FACTOR; AGING; CHEMICALLY INDUCED DISORDER; EMERGENCY HEALTH SERVICE; METABOLISM; UNIVERSITY HOSPITAL;

AGED; AGING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR AGENTS; CASE-CONTROL STUDIES; CREATININE; DIABETES COMPLICATIONS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALS, UNIVERSITY; HUMANS; HYPERKALEMIA; MALE; RISK FACTORS;

EID: 23844451243     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00638.x     Document Type: Article

References (21)

1. Cruz CS, Cruz AA, Marcilio de Souza CA (2003) Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrology, Dialysis, Transplantation, 18, 1814-1819.
2. The RALES investigators (1996) Effectiveness of spironolactone added to angiotensin-converting enzyme inhibitor and loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology, 78, 902-907.
3. Anton C, Cox AR, Watson RD, Ferner RE (2003) The safety of spironolactone treatment in patients with heart failure. Journal of Clinical Pharmacy and therapeutics, 28, 285-287.
4. Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. New England Journal of Medicine, 351, 585-592.
5. Obialo CI, Ofili EO, Mirza T (2002) Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. American Journal of Cardiology, 90, 663-665.
6. Ahee P, Crowe AV (2000) The management of hyperkalemia in the emergency department. Journal of Accident and Emergency Medicine, 17, 188-191.
7. Juurlink DN, Mamdani MM, Lee DS et al. (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. New England Journal of Medicine, 351, 543-551.
8. Svensson M, Gustafsson F, Galatius S et al. (2003) Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ, 327, 1141-1142.
9. Svensson M, Gustafsson F, Galatius S et al. (2004) How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? Journal of Cardiac Failure, 10, 297-303.
10. Criteria Committee of the New York Heart Association (1964) Nomenclature and criteria for the diagnosis of diseases of the heart and great vessels, 6th edn. Boston: Little Brown.
11. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
12. Charlson ME, Ponpei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40, 373-383.
13. Jarman PR, Kehley AM, Mather HM (1995) Hyperkalemia in diabetes: prevalence and associations. Postgraduate Medical Journal, 71, 551-552.
14. Odawara M, Asano M, Yamashita K (1997) Life-threatening hyperkalemia caused by angiotensin-converting enzyme-inhibitor and diuretics. Diabetic Medicine, 14, 169-170.
15. Walmsley RN, White GH, Cain M et al. (1984) Hyperkalemia in the elderly. Clinical Chemistry, 30, 1409-1412.
16. Beck LH (1998) Changes in renal function with aging. Clinics in Geriatric Medicine, 14, 199-209.
17. Perazella MA, Mahnensmith RL (1997) Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. Journal of General Internal Medicine, 12, 646-656.
18. Ponce SP, Jennings AE, Madias NE et al. (1985) Drug-induced hyperkalemia. Medicine, 64, 357-370.
19. Greenblatt DJ, Koch-Weser J (1973) Adverse reactions to spironolactone. JAMA, 225, 40-43.
20. Textor SC, Bravo EL, Fouad FM et al. (1982) Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. American Journal of Medicine, 73, 719-725.
21. Atlas SA, Case DB, Sealey JE et al. (1979) Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension, 1, 274-280.